The Effects of Ginkgo biloba Extracts on the Pharmacokinetics and Pharmacodynamics of Donepezil
Authors:
- 1 May 2004
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 44 (5) , 538-542
Abstract
The effects of ginkgo supplementation on the steady‐state plasma concentration of donepezil and the activity of cholinesterase in red blood cells and cognitive function were examined. Fourteen inpatients with Alzheimer's disease received donepezil 5 mg/day, supplemented with extracts of Ginkgo biloba 90 mg/day for 30 days. Blood samples were collected before and during ginkgo supplementation and 30 days after its discontinuation, together with an assessment of cognitive function. Plasma drug concentration was measured using high‐performance liquid chromatography (HPLC), and cholinesterase in red blood cells was measured using Ellman methods. Cognitive function was evaluated using the Mini‐Mental Scale Examination (MMSE). Plasma concentration of donepezil during ginkgo supplementation (mean ± SD [95% confidence interval]; 24.4 ± 12.6 ng/mL [17.1–31.7 ng/mL]) was not significantly different from that before ginkgo supplementation (22.7 ± 10.3 ng/mL [16.8–28.7 ng/mL]) or that 4 weeks after its discontinuation (25.0 ± 12.9 ng/mL [17.6–32.4 ng/mL]). There was no significant difference between cholinesterase in red blood cells before ginkgo supplementation (1.75 ± 0.21 U [1.63–1.87 U]), during ginkgo supplementation (1.91 ± 0.27 U [1.76–2.07 U]), and 4 weeks after its discontinuation (1.83 ± 0.29 U [1.66–2.00 U]). Ginkgo supplementation did not alter MMSE scores throughout the study. The present study shows that ginkgo supplementation does not have major impact on the pharmacokinetics and pharmacodynamics of donepezil.Keywords
This publication has 18 references indexed in Scilit:
- Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detectionJournal of Chromatography B, 2002
- Influence of the Severity of Cognitive Impairment on the Effect of the Ginkgo biloba Extract EGb 761® in Alzheimer’s DiseaseNeuropsychobiology, 2002
- A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s diseaseNeurology, 2001
- Herbal Medicines and Perioperative CareJAMA, 2001
- Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral dosesBritish Journal of Clinical Pharmacology, 1998
- Combination Therapy for Early Alzheimer's Disease: What Are We Waiting for?Journal of the American Geriatrics Society, 1998
- Donepezil Improves Cognition and Global Function in Alzheimer DiseaseA 15-Week, Double-blind, Placebo-Controlled StudyArchives of internal medicine (1960), 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- A double-blind, placebo controlled study of Ginkgo biloba extract (‘Tanakan’) in elderly outpatients with mild to moderate memory impairmentCurrent Medical Research and Opinion, 1991
- Comparison of acetylcholinesterase determinations by the Michel and Ellman methodsAnalytical Chemistry, 1972